Allergy Department, "Carol Davila" University of Medicine & Pharmacy, Bucharest, 020021, Romania.
Allergy Department, Nephrology Hospital Dr. Carol Davila, Bucharest, 010731, Romania.
Immunotherapy. 2022 Jun;14(8):627-638. doi: 10.2217/imt-2021-0325. Epub 2022 Apr 13.
Allergen immunotherapy (AIT) is considered the only disease-modifying treatment available at present for allergic disorders. Its main benefits include improvement of symptoms, decreased need for pharmacotherapy, prevention of new sensitizations and sustained effect after AIT completion. The key pillars of AIT-induced tolerance include a shift from Th2 to Th1 response, an increase of regulatory T and B cells, pro-inflammatory effector cell downregulation and IgE suppression, in addition to IgG4, IgA and IgD induction. AIT may also induce trained immunity, characterized by a durable decrease in group 2 of innate lymphoid cells (ILCs) and increased ILC1 and ILC3s. Understanding the immune mechanisms of AIT is essential for validating biomarkers for the prediction of AIT response and for achieving AIT success.
变应原免疫疗法(AIT)被认为是目前治疗过敏疾病的唯一可改变疾病进程的治疗方法。其主要益处包括改善症状、减少药物治疗的需求、预防新的致敏和 AIT 完成后的持续效果。AIT 诱导耐受的关键支柱包括从 Th2 向 Th1 反应的转变、调节性 T 和 B 细胞的增加、促炎效应细胞的下调和 IgE 的抑制,以及 IgG4、IgA 和 IgD 的诱导。AIT 还可能诱导训练有素的免疫,其特征是 2 组固有淋巴细胞(ILC)的持久减少和 ILC1 和 ILC3 的增加。了解 AIT 的免疫机制对于验证预测 AIT 反应的生物标志物和实现 AIT 的成功至关重要。